CN1978642A - Human hLDP gene sequence, and its coded protein and preparing method - Google Patents
Human hLDP gene sequence, and its coded protein and preparing method Download PDFInfo
- Publication number
- CN1978642A CN1978642A CN 200510111047 CN200510111047A CN1978642A CN 1978642 A CN1978642 A CN 1978642A CN 200510111047 CN200510111047 CN 200510111047 CN 200510111047 A CN200510111047 A CN 200510111047A CN 1978642 A CN1978642 A CN 1978642A
- Authority
- CN
- China
- Prior art keywords
- hldp
- sequence
- people
- polypeptide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 44
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 71
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
- 108091026890 Coding region Proteins 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 53
- 108020004414 DNA Proteins 0.000 claims description 35
- 235000018102 proteins Nutrition 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 14
- 238000012408 PCR amplification Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000006870 function Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 2
- 230000008827 biological function Effects 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 29
- 239000002299 complementary DNA Substances 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 241000238631 Hexapoda Species 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003016 hypothalamus Anatomy 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 102100026679 Carboxypeptidase Q Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- -1 50 μ l Substances 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102100028929 Formin-1 Human genes 0.000 description 1
- 101000847530 Gallus gallus Formin Proteins 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101001059390 Homo sapiens Formin-1 Proteins 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001059391 Mus musculus Formin-1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012254 genetic linkage analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a new hLDP protein' coding sequence and its expression in a normal human pituitary. The hLDP protein belonged to the new protein gene expression, and has never been opened. The invention also opened the methods of preparation of the protein and nucleic acid, and the detection methods of hLDP sequence and peptide in samples. The further research on hLDP will revealed the function of hLDP in human body, thus helping people to better understand and use the biological function of new opened hLDP, and bring it to the clinical application.
Description
Technical field
The invention discloses a kind of nucleotide sequence and encoded protein thereof of Human genome.Particularly, the present invention relates to a kind of hLDP albumen and nucleotide sequence thereof of in human hypothalamus, expressing.The invention still further relates to the preparation method of this albumen and nucleotide sequence.
Background technology
Functions such as the motion of cell cortex, adhesion and division of cytoplasm all are to regenerate by the reorganization of actin cytoskeleton to realize.The assembling process of the building block of cytoskeleton in cortex is subjected to the dynamic adjustments on time, the space.Recent result of study shows that limb deformation protein (Limb deformity protein, LDP, i.e. Formin) family is playing keying action aspect the reorganization regeneration of cytoskeleton.(Biochem BiophysRes Commun 2000 Jan 19；267(2)：479-81)。
Among the present invention, we are cloned into the homologous gene hLDP of chicken LDP gene in human hypothalamus.
Before the present invention comes forth, any human hLDP protein sequence and nucleotide sequence of mentioning in the present patent application thereof that disclose or reported do not arranged as yet.
Summary of the invention
Technical problem to be solved by this invention provides nucleotide sequence and its encoded protein matter of a kind of new people's gene hLDP (GenbankAccession No.AF225426), and utilizes recombinant technology to produce the above-mentioned new people hLDP albumen and the preparation method of nucleotide sequence.
For solving the problems of the technologies described above, the invention provides a kind of isolated dna molecular, this molecule comprises: coding has the nucleotide sequence of the polypeptide of people hLDP protein active, shows at least 70% homology from the nucleotides sequence of Nucleotide 228-827 position dna molecular among described nucleotide sequence and the SEQ IDNO.6; Perhaps described nucleotide sequence can be under the moderate stringent condition with SEQ ID NO.6 in from the nucleotide sequence hybridization of Nucleotide 228-827 position.Preferably, described sequence encoding has the polypeptide of the aminoacid sequence shown in the SEQ ID NO.7.More preferably, described sequence has among the SEQ ID NO.6 nucleotide sequence from Nucleotide 228-827 position.
The present invention also provides a kind of isolated people hLDP protein and peptide, and it comprises: have polypeptide or its conservative property variation polypeptide or its active fragments of SEQ ID NO.7 aminoacid sequence, or its reactive derivative.Preferably, this polypeptide is to have SEQ ID NO.7 polypeptide of sequence.
The present invention also provides a kind of carrier, and it comprises above-mentioned dna molecular.
The present invention also provides a kind of usefulness above-mentioned carrier transformed host cells.This host cell is intestinal bacteria in an example; In another example, this host cell is an eukaryotic cell.
The present invention also provides a kind of generation to have the method for the polypeptide of people hLDP protein active, its step is as follows: (1) operationally is connected in expression regulation sequence with the nucleotide sequence that coding has the polypeptide of people hLDP protein-active, form people hLDP protein expression vector, show at least 70% homology from the nucleotides sequence of Nucleotide 228-827 position among described nucleotide sequence and the SEQ ID NO.6;
(2) change the expression vector in the step (1) over to host cell, form the proteic reconstitution cell of people hLDP;
(3) under the condition that is fit to expressing human hLDP protein polypeptide, the reconstitution cell in the culturing step (2);
(4) isolate polypeptide with people hLDP protein-active.
Preferably, the nucleotide sequence that uses in the method has the sequence of 228-827 position among the SEQ ID NO.6.
The present invention also provides and hLDP protein polypeptide specificity bonded antibody.
In the present invention, " isolating ", " purifying " or " pure substantially " DNA are meant, this DNA or fragment have been arranged in the sequence of its both sides and have separated under native state, refer to that also this DNA or fragment with under the native state follow the component of nucleic acid to separate, and separate with the protein of in cell, following it.
In the present invention, term " people hLDP albumen (or polypeptide) encoding sequence " refer to the encode nucleotide sequence of polypeptide with people hLDP protein-active is as 228-827 position nucleotide sequence and degenerate sequence thereof among the SEQ ID NO.6.This degenerate sequence is meant, is arranged in the encoder block 228-827 position Nucleotide of SEQ ID NO.6 sequence, and having one or more codons to be encoded, the degenerate codon of same amino acid replaces the back and the sequence that produces.Because the degeneracy of codon, thus with SEQ ID NO.6 in 228-827 position nucleotide sequence homology be low to moderate about 70% the degenerate sequence described sequence of SEQ ID NO.7 of also encoding out.This term also comprises can be under the moderate stringent condition, better under the height stringent condition with SEQ ID NO.6 in from the nucleotide sequence of the nucleotide sequence hybridization of Nucleotide 228-827 position.This term also comprise with SEQ ID NO.6 in from the homology of nucleotide sequence at least 70% of Nucleotide 228-827 position, preferably at least 80%, more preferably at least 90%, at least 95% nucleotide sequence best.
This term also comprises encoding to have the variant form of open reading frame sequence among proteic, the SEQ ID NO.6 with natural people hLDP identical function.These variant forms comprise (but being not limited to): several (are generally 1-90, preferably 1-60, more preferably 1-20,1-10 best) disappearance, insertion and/or the replacement of Nucleotide, and several (are generally in 60 to hold interpolation 5 ' and/or 3 ', preferably being in 30, more preferably is in 10, is in 5 best) Nucleotide.
In the present invention, " pure substantially " protein or polypeptide are meant that it accounts at least 20% of the total material of sample at least, preferably at least 50%, more preferably at least 80%, and at least 90% (by dry weight or weight in wet base) best.Purity can be measured with any suitable method, as measure the purity of polypeptide with column chromatography, PAGE or HPLC method.Substantially pure polypeptide is substantially free of the component of following it under the native state.
In the present invention, term " people hLDP albumen or polypeptide " refers to have the SEQ IDNO.7 polypeptide of sequence of people hLDP protein-active.This term also comprises having and variant form natural human hLDP identical function, SEQ ID NO.7 sequence.These variant forms comprise (but being not limited to): several (are generally 1-50, preferably 1-30, more preferably 1-20,1-10 best) amino acid whose disappearance, insertion and/or replacement, and add one or several at C-terminal and/or N-terminal and (be generally in 20, preferably being in 10, more preferably is in 5) amino acid.For example, in the art, when replacing, can not change proteinic function usually with the close or similar amino acid of performance.Again such as, add one or several amino acid at C-terminal and/or N-terminal and also can not change proteinic function usually.This term also comprises proteic active fragments of people hLDP and reactive derivative.
The variant form of people hLDP polypeptide of the present invention comprises: homologous sequence, conservative property varient, allelic variant, natural mutation, induced mutation body, under high or low stringent condition can with the coded albumen of the DNA of people hLDP DNA hybridization and the polypeptide or the albumen that utilize the antiserum(antisera) of anti-people hLDP polypeptide to obtain.The present invention also provides other polypeptide, as comprises people hLDP polypeptide or its segmental fusion rotein.Except the polypeptide of total length almost, the present invention also comprises the soluble fragments of people hLDP polypeptide.Usually, this fragment have people hLDP peptide sequence at least about 10 continuous amino acids, usually at least about 30 continuous amino acids, preferably at least about 50 continuous amino acids, more preferably at least about 80 continuous amino acids, best at least about 100 continuous amino acids.
In the present invention, " people hLDP conservative property variation polypeptide " refers to compare with the aminoacid sequence of SEQ ID NO.7, has 10 at the most, and preferably at the most 8, more preferably 5 amino acid is replaced by similar performance or close amino acid and formed polypeptide at the most.These conservative property variation polypeptide are preferably replaced according to table 1 and are produced.
Table 1
| Initial residue | Representational replacement | The preferred replacement |
| Ala(A) | Val；Leu；Ile | Val |
| Arg(R) | Lys；Gln；Asn | Lys |
| Asn(N) | Gln；His；Lys；Arg | Gln |
| Asp(D) | Glu | Glu |
| Cys(C) | Ser | Ser |
| Gln(Q) | Asn | Asn |
| Glu(E) | Asp | Asp |
| Gly(G) | Pro；Ala | Ala |
| His(H) | Asn；Gln；Lys；Arg | Arg |
| Ile(I) | Leu；Val；Met；Ala；Phe | Leu |
| Leu(L) | Ile；Val；Met；Ala；Phe | Ile |
| Lys(K) | Arg；Gln；Asn | Arg |
| Met(M) | Leu；Phe；Ile | Leu |
| Phe(F) | Leu；Val；Ile；Ala；Tyr | Leu |
| Pro(P) | Ala | Ala |
| Ser(S) | Thr | Thr |
| Thr(T) | Ser | Ser |
| Trp(W) | Tyr；Phe | Tyr |
| Tyr(Y) | Trp；Phe；Thr；Ser | Phe |
| Val(V) | Ile；Leu；Met；Phe；Ala | Leu |
Invention also comprises the analogue of people hLDP albumen or polypeptide.The difference of these analogues and natural human hLDP polypeptide can be the difference on the aminoacid sequence, also can be the difference that does not influence on the modified forms of sequence, perhaps haves both at the same time.These polypeptide comprise natural or the inductive genetic variant.The induce variation body can obtain by various technology, as by radiation or be exposed to mutagenic compound and produce random mutagenesis, also can pass through site-directed mutagenesis method or the biological technology of other known moleculars.Analogue also comprises having the analogue that is different from the amino acid whose residue of natural L-(as D-amino acid), and has non-natural analogue that exist or synthetic amino acid (as β, gamma-amino acid).Should be understood that polypeptide of the present invention is not limited to the above-mentioned representational polypeptide that exemplifies.
(the not changing primary structure usually) form of modification comprises: the chemically derived form such as the acetylize or carboxylated of the polypeptide that body is interior or external.Modification also comprises glycosylation, carries out glycosylation modified and polypeptide that produce in the procedure of processing as those in the synthetic and processing of polypeptide or further.This modification can be carried out glycosylated enzyme (as mammiferous glycosylase or deglycosylating enzyme) and finishes by polypeptide is exposed to.Modified forms also comprises have the phosphorylated amino acid residue sequence of (as Tyrosine O-phosphate, phosphoserine, phosphothreonine).Thereby also comprise the polypeptide that has been improved its anti-proteolysis performance or optimized solubility property by modifying.
In the present invention, can select various carrier known in the art for use, the carrier as commercially available comprises plasmid, clay etc.When producing people hLDP polypeptide of the present invention, people hLDP encoding sequence operationally can be connected in expression regulation sequence, thereby form people hLDP protein expression vector.
As used herein, " operationally being connected in " refers to a kind of like this situation, and promptly some part of linear DNA sequence can influence the activity of same other parts of linear DNA sequence.For example, if signal peptide DNA as precursor expression and participate in the secretion of polypeptide, signal peptide (secretion leader sequence) DNA operationally is connected in polypeptid DNA so; If transcribing of promotor control sequence, it is operationally to be connected in encoding sequence so; When if ribosome bind site is placed in the position that can make its translation, it is operationally to be connected in encoding sequence so.Generally, " operationally being connected in " means adjacent, then means in reading frame adjacent for the secretion leader sequence.
In the present invention, term " host cell " comprises prokaryotic cell prokaryocyte and eukaryotic cell.The example of prokaryotic host cell commonly used comprises intestinal bacteria, Bacillus subtilus etc.Eukaryotic host cell commonly used comprises yeast cell, insect cell and mammalian cell.Preferably, this host cell is an eukaryotic cell, as Chinese hamster ovary celI, COS cell etc.
The present invention also provides people hLDP specificity bonded antibody, comprises polyclonal antibody and monoclonal antibody.
In the present invention, can use a series of methods known in the art to prepare special antibody at people hLDP.For example, the people hLDP gene product or its antigen fragment of purifying is injected in the animal body to produce polyclonal antibody.Equally, the cell of expressing human hLDP or its antigen fragment also can be used for animal is caused immunity and produces antibody.Antibody prepared in accordance with the present invention also can be monoclonal antibody, and these monoclonal antibodies can prepare (for example, Kohler et al., Nature 256:495,1975 with hybridoma technology; Kohleret al., Eur.J.Immunol.6:511,1976; Kohler et al., Eur.J.Immunol.6:292,1976).Antibody of the present invention comprises the antibody that can prevent people hLDP function, also can be the antibody that does not influence people hLDP function.Each antibody-like can produce by the fragment of people hLDP gene product or functional domain are caused immunity, and people hLDP gene product and fragment thereof can produce or synthesize with Peptide synthesizer with recombination method.With the people hLDP gene product bonded antibody of non-modified forms, can come immune animal to obtain by being used in the gene product that prokaryotic cell prokaryocyte for example produces among the E.coli.With posttranslational modification form such as glycosylation or phosphorylated protein or polypeptide bonded antibody, can obtain by the immune animal that comes that is used in the gene product that produces in eukaryotic cell such as yeast or the insect cell.
People hLDP antibody of the present invention can be used for identifying the cell of expressing human hLDP albumen or polypeptide, as Jurkat T cell.For example, can with a kind of detectable molecule for example fluorescein isothiocyanic acid (FITC) come labelling human hLDP specific antibody, allow people hLDP specific antibody contact then, detect and people hLDP specific antibody bonded cell with fluorescent microscope or flow cytometer again with cell sample.
Except cell surface detects people hLDP, can also analyze this protein with the Western engram technology.Cell pyrolysis liquid can from culturing cell or take from patient's tissue sample such as hypothalamus extract, and be dissolved in the lysis buffer that contains stain remover.Use sds polyacrylamide gel electrophoresis isolated cell extract (simultaneously with the people hLDP polypeptide of purifying as positive control) then, then it is transferred on the nitrocellulose by electrophoresis hybridization.In order to survey people hLDP polypeptide, can use typical antibodies detection method, for example radioautograph or alkaline phosphatase enzyme assay method with the immunity of Western trace.And can use the contrast of immunization serum or incoherent monoclonal antibody as non-specific responding.
Whether and quantity the expression of also available Nothern blotting technical Analysis people hLDP gene product, the i.e. existence of rna transcription thing in cell of analyst hLDP.
The Western engram analysis of the Nothern engram analysis of people hLDP DNA and people hLDP specific antibody can be united use, with the expression of confirmer hLDP in biological specimen.People hLDP DNA can also be used for Southern engram analysis or in situ hybridization analysis, with this assignment of genes gene mapping on karyomit(e), and can carry out genetic linkage analysis to find out other possible disease related gene.
In addition, the present invention also provides a kind of nucleic acid molecule that can be used as probe, and this molecule has 8-100 continuous nucleotide of people hLDP nucleotide coding sequence usually, preferably has 15-50 continuous nucleotide.This probe can be used for whether existing in the test sample nucleic acid molecule of coding people hLDP.
The present invention also provides the method that whether has people hLDP nucleotide sequence in the test sample, and it comprises with above-mentioned probe and sample and hybridizing whether detection probes combination has taken place then.Preferably, this sample is the product behind the pcr amplification, and wherein the pcr amplification primer is corresponding to people hLDP nucleotide coding sequence, and can be positioned at the both sides or the centre of this encoding sequence.Primer length is generally 15-50 Nucleotide.
In addition, according to people hLDP nucleotide sequence of the present invention and aminoacid sequence, can be on the homology basis of nucleic acid homology or marking protein, screening people's hLDP homologous gene or homologous protein.
In order to obtain and the people cDNAs of people hLDP gene-correlation or the dot matrix of genomic dna s, can screen people cDNA or genome dna library with dna probe, these probes are under low stringent condition, use
32P people hLDP all or part of cooked the radioactivity mark and.The cDNA library that most is suitable for screening is from the hypothalamic library of people.Also can be used for screening purpose from the cDNA library that participates in endocrine other tissue or specific human body cell strain.Structure is that biology field is well-known from the method in the cDNA library of interested cell or tissue.In addition, many such cDNA libraries also can buy, for example available from Clontech, and Palo Alto, Cal..This screening method can be discerned the nucleotide sequence of the gene family relevant with people hLDP.
Can finish as follows according to Nucleotide similarity screening people hLDP homologue.Human hypothalamic cDNA library, for example (Clontech, Palo Alto Cal.) can use one section all or part of random primer dna probe screening that comprises human hLDP gene sequence to Clontech Cat.#74XX.Finish having clone's the evaluation of the DNA insertion sequence of 70% homology at least with people hLDP sequence, can use hybridization temperature is 55 ℃ hybridization solution, uses 0.5 * SSC and 0.1%SDS to clean then.Shi Bie clone's DNA insertion sequence can be further estimated the similarity of it and people hLDP gene with DNA restriction endonuclease analysis and dna sequencing in this way.The distribution of tissue expression can be with above-mentioned Northern blotting technical Analysis.
People hLDP homologue also can be used at the antibody of people hLDP albumen or polypeptide and discern.For example, can be with the method for standard to commercial or make up with currently known methods, from cell or organize for example hypothalamic expression library to screen.Pour the library into plate, on colony lift to a nitrocellulose membrane, the recombinant protein of expression is attached on the film.Just can carry out typical antibodies and detection then with specific people hLDP antibody.Identify the DNA insertion sequence among the clone in this way, can be further analyze to estimate the similarity of it and people hLDP gene with DNA restriction endonuclease analysis and dna sequencing.The tissue expression of the gene of new identification distributes and can similarly analyze as stated above.
People hLDP Nucleotide full length sequence of the present invention or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.
In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.
In addition, also the method for available artificial chemosynthesis is synthesized relevant sequence.Before the application, prior art fully can be by first synthetic a plurality of polynucleotide small segments, and then connect and obtain the proteic nucleotide sequence of code book contriver hLDP.Then, can be with in various existing dna moleculars (as carrier) and the cell in this nucleotide sequence introducing this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.
Except producing with recombination method, the also available solid phase technique of the proteic fragment of the present invention is produced (people such as Stewart, (1969) Solid-Phase Peptide Synthesis, WHFreeman Co., San Francisco by direct peptide synthesis; Merrifield J. (1963) J.Am Chem.Soc 85:2149-2154).Can carry out by hand or automatically at external synthetic protein.For example, can (Foster City CA) synthesizes peptide automatically with the 431A type peptide synthesizer of AppliedBiosystems.Can distinguish proteic each fragment of chemosynthesis the present invention, be connected to produce the molecule of total length with chemical process then.
The proteic encoding sequence of the present invention can be used for the assignment of genes gene mapping.For example,, the cDNA clone is hybridized with the karyomit(e) of metaphase, can carry out chromosomal localization exactly by fluorescence in situ hybridization technique (FISH).This technology can be used the cDNA that is as short as about 500bp; Also can use and grow to about 2000bp or longer eDNA.For this technology, can be referring to people such as Verma, Human Chromosomes:A Manual ofBasic Techniques, Pergamon Press, New York (1988).
In case sequence is located in certain exact position on the karyomit(e), the physical location of sequence on karyomit(e) can be associated with the genetic map data.These genetic map data can obtain, for example by Mendelian (Mendelian) people genetic database (can obtain on the net by Johns Hopkins University WelchMedical Library).Then, come identified gene by linkage analysis and be positioned dependency between the disease of same chromosomal region.
Then, be necessary to determine the cDNA between diseased individuals and the healthy individual or the difference of genome sequence aspect.Be not present in normal individual if a certain sudden change is present in part or all of diseased individuals, this sudden change may be exactly the paathogenic factor of this disease so.
Utilize people hLDP albumen of the present invention,, can filter out with people hLDP interactional material takes place, perhaps acceptor, inhibitor or antagonist etc. by various conventional screening methods.
Inventor hLDP albumen and antibody thereof, inhibitor, antagonist or acceptor etc. when using (administration) in treatment, can provide different effects.Usually, can these materials are formulated in nontoxic, inert and the pharmaceutically acceptable aqueous carrier medium, wherein pH is generally about 5-8, and preferably pH is about 6-8, although the pH value can be with being changed to some extent by preparation Substance Properties and illness to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, intracutaneous or topical.
With people hLDP albumen of the present invention is example, can be with itself and suitable pharmaceutically acceptable carrier coupling.This class pharmaceutical composition contains protein and the pharmaceutically acceptable carrier or the vehicle for the treatment of significant quantity.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.People hLDP albumen of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.
When people hLDP protein polypeptide of the present invention is used as medicine, this polypeptide of treatment effective dose can be applied to Mammals, wherein should treat effective dose usually at least about 10 micrograms/kg body weight, and in most of the cases be no more than about 8 mg/kg body weight, preferably this dosage is about 10 micrograms/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
Table 2 is that the homology of people hLDP albumen of the present invention and the proteic aminoacid sequence of chicken LDP (GenPeptAccession No.Q05858) compares (FASTA) figure.Wherein, identical amino acid marks asking with the amino acid monocase of two sequences, and similar amino acid marks with "+".
Table 2
47.1％identity in 172 aa overlap，80.2％similarity in 172 aa overlap
10 20 30 40 50
h.pep MSRAVTIAEAFCHILFRIISEILMRMLGKEQCLFPLPEPRDLFQASQMKFEVFQKDL
| ++ +||||||+|+|||||+||| + |||
g.pep KLKDVKSRDNRINLVDYVVIYYLRHCDKEAGTDKSIFPLPEPQDFFQASQVKFEDLIKDL
1010 1020 1030 1040 1050 1060
60 70 80 90 100 110
h.pep RKLRKDLKACEVEAGKVYQVSSKEHMQPFKENMEQFIIQAKIDQEAEENSLTETHKCFLE
|||++||+| | + | + ||+||+|||||++|+|++|| +++ ||+|| +++||| |
g.pep RKLKRDLEASEKQMKLVCRESSEEHLQPFKEKLEEFFQKAKEERKKEESSLENAQKCFEE
1070 1080 1090 1100 1110 1120
120 130 140 150 160 170
h.pep TTAYFFMKPKLGEKEVSPNAFFSIWHEFSSDFKDFWKKENKLLLQERVKEAEE-VCRQKK
|++|| +||| ||||++|| |++|+|| |||| +||+|+| + +||+| |++ | +
g.pep TVGYFGIKPKPGEKEITPNYVFTVWYEFCSDFKTIWKRESKSISKERIKVAQQSVSKLTA
1130 1140 1150 1160 1170 1180
180 190 199
h.pep GKSLYKIKPRHDSGIKAKISMKT
|++ | +++| ++ +|
g.pep EKKVETKKINPTASLKERLRQKEANVNAN
1190 1200 1210
H.pep: people hLDP Argine Monohydrochloride sequence
G.pep: chicken LDP Argine Monohydrochloride sequence (GenBank Accession No.Q05858)
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1
The clone of people hLDP gene
1. separate tissue (hypothalamus isolation)
Hypothalamus derives from 5 normal adult male sex donors, takes out hypothalamus in after death four hours, places the freezing preservation of liquid nitrogen immediately.
2.mRNA separation (mRNA isolation)
Take out tissue, grind, add the 50ml pipe that fills lysate, fully after the vibration, move in the glass homogenizer again with mortar.Move to 50ml after the homogenate and newly manage, and extracted total RNA (TRIzol Reagents, Gibco, NY, USA).Identify total RNA quality with the denaturing formaldehyde gel electrophoresis.Cellulose column with band Oligo d (T) separates mRNA among total RNA, quantitatively.
3.cDNA the structure in library (Construction of cDNA library)
With mRNA is template, and synthetic double chain cDNA, reverse transcription primer are seen SEQ ID NO.1.After mending flat end, add the joint that contains the EcoRI point of contact, joint sequence is seen SEQ ID NO.2 and 3 respectively.Behind the phosphorylation EcoRI end, use XhoI digestion with restriction enzyme 1.5 hours, carry out fragment again and separate.Cross the fragment of post screening length＞500bp, use the phenol-chloroform extracting, ethanol sedimentation, the sterilized water dissolving, be connected to Uni-ZAP XR carrier (Stratagene, CA9203, USA), with Zap-cDNA Gigapack III Gold Cloning Kit (Stratagene, CA9203 USA) packs, and the host bacterium is used XL 1-Blue MRF ' (Stratagene, CA9203, USA) bacterium.Coated plate is also measured titre.
4. order-checking and database are set up (Seqencing and Database Constructing)
Select the clone who has the external source fragment to insert in the library, amplification back extracting plasmid (Qiagen, Germany), hold as 3 ' and the 5 ' universal primer of holding with T3 and T7, adopt thing fluorescent mark (Big-Dye, Perkin-Elmer, method USA) of stopping, (Perkin-Elmer carries out the EST large scale sequencing on USA) at ABI 377 sequenators.Sequencing result is removed the carrier sequence with FACTURA software, is transferred to the processing of carrying out next step on the SUN Ultra 450Server.All sequence informations are used the GCG software package again, and (Wisconsingroup, USA) BLAST in and the existing database of FASTA software search (Genebank+EMBL) are lower than 95% sequence with no homology or homology and are considered as new gene and set up database.
5. the full-length clone of gene (Cloning of Full-length cDNA)
On the new gene fragment order information basis that obtains, carry out the cDNA full-length clone, carry out in two stages:
(1) " electronic cloning " (Electronic Cloning)
Search the dbEST database with new gene fragment order as probe, with overlap＞50bp, homology is at (the Expressed Sequence Tag of the expressed sequence tag more than 98%, being called for short " EST ") sequence thinks same sequence (consensus sequence), take out and splice with AUTOASSEMBLER software, part EST can the extension probes sequence.Whether the sequence that is extended with the STRIDER software analysis has complete open reading frame (Open Reading Frame again, ORF), on Nucleotide and amino acid levels, whether homology is arranged with definite this sequence with BLAST search Genbank or SwissProt, to help how differentiate resulting full length gene integrity with other species.By the method for electronic cloning, can obtain the full length sequence of people hLDP gene usually.
(2) the terminal rapid amplifying of cDNA (Rapid Amplification of cDNA Ends, RACE)
If do not obtain complete cDNA total length yet by " electronic cloning " method, then at 5 ' or 3 ' end design primer of existing sequence, (Clontech Lab, Inc carry out the long range PCR reaction in USA) in human hypothalamus Marathon-Ready cDNA library.Then to PCR product cloning, order-checking.The sequence that is extended with AUTOASSEMBLER and STRIDER software analysis has or not complete ORF, as not having, repeats said process until obtaining total length.
(3)RT-PCR
For 5 ' and 3 ' end known sequences,, can consider to adopt the method for RT-PCR if the centre still has an intersegmental crack (gap) to obtain from existing public database or its data storehouse.At sequence 5 ' end design primer, 3 ' end primer adopts Oligo-dT, increases in the total RNA of hypothalamus storehouse.Then product is cloned, checked order.Splice at last and obtain total length.
By being used in combination above-mentioned 3 kinds of methods, obtained candidate's the proteic complete encoding sequence of people hLDP.Obtain on the total length basis of (comprising complete open reading frame at least) in splicing, further R1:5 '-GAGCGAGTCTTTTGCATCCT-3 ' (SEQ ID NO.4) is a forward primer to the design primer, oligonucleotide R2:5 '-GACTGAAGGGGACAGGAAGA-3 ' (SEQ ID NO.5) is a reverse primer, with hypothalamic total RNA is template, carry out the RT-PCR amplification, the PCR condition of R1/R2 be 94 ℃ 5 minutes, carried out 35 circulations in 1 minute with 94 ℃ 30 seconds, 60 ℃ 30 seconds and 72 ℃ thereupon, extended 5 minutes with 72 ℃ at last.The electrophoresis detection pcr amplification product, the acquisition expanding fragment length is 1701bp.Clone, check order with pcr amplification product according to a conventional method then, obtain the sequence shown in the SEQ ID NO.6.
Embodiment 2
The sequence information and the homology analysis of people hLDP gene:
People hLDP full-length cDNA (the GenBank Accession No.AF225426 that the present invention is new.Unexposed mistake before the application) length is 1701bp, and detailed sequence is seen SEQ ID NO.6, and wherein open reading frame is positioned at 228--827 position Nucleotide.Derive the aminoacid sequence of people hLDP according to full-length cDNA, totally 199 amino-acid residues, molecular weight 23511.45, pI are 8.97.Detailed sequence is seen SEQ ID NO.7.
The protein sequence of hLDP is carried out the protein homology retrieval with blast program in Non-redundant GenBank CDStranslations+PDB+SwissProt+Superdate+PIR database, found that there is certain homology in the LDP gene of it and chicken.On amino acid levels, the 1036-1210 amino acids residue of it and chicken LDP albumen (GenPept Accession No.Q05858) has 47.1% homogeny and 80.2% similarity (subordinate list 2).Therefore there are higher homology in hLDP gene and chicken LDP gene on protein level, can think that both also have very high similarity on function.
People hLDP of the present invention is used for further functional study except can be used as this family's a member, also can be used for producing fusion rotein with other albumen, such as producing fusion rotein with immunoglobulin (Ig).In addition, people hLDP of the present invention can also merge with other members of this family or exchange fragment, to produce new albumen.For example proteic N end of people hLDP of the present invention and the proteic N end of chicken LDP are exchanged, to produce the albumen that new activity is higher or have new features.
At the antibody of inventor hLDP, be used to screen other members of this family, perhaps be used for affinity purification associated protein (as other members of this family).
In addition, inventor hLDP nucleic acid (encoding sequence or antisense sequences) can be introduced into cell, with expression level that improves people hLDP or the overexpression that suppresses people hLDP.People hLDP albumen of the present invention or its active polypeptide fragment can be applied to patient, with treatment or alleviate because of people hLDP disappearance, no function or unusual cause related disorders arranged.In addition, can also be with carrying out relevant diagnosis or prognosis judgement based on nucleotide sequence of the present invention or antibody.
Because people hLDP albumen of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species (as chicken), estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.
Embodiment 3
The proteic 26S Proteasome Structure and Function research of people hLDP:
With the proteic aminoacid sequence of people hLDP the blocks database (network address is: index structure territory http://www.blocks.fhcrc.org) obtains following result:
1 MSRAVTIAEA FCHILFRIIS EILMRMLGKE QCLFPLPEPR DLFQASQMKF
51 EVFQKDLRKL RKDLKACEVE AGKVYQVSSK EHMQPFKENM EQFIIQAKID
101 QEAEENSLTE THKCFLETTA YFFMKPKLGE KEVSPNAFFS IWHEFSSDFK
151 DFWKKENKLL LQERVKEAEE VCRQKKGKSL YKIKPRHDSG IKAKISMKT
(1) in aminoacid sequence, there is following structural domain district:
Add the frame district (41-62,137-156): limb deformation protein signal (Formin signature)
(2) functional analysis
In this aminopeptidase gene acid sequence, there is limb deformation protein signal (Formin signature), thereby can predicts it and have corresponding function really.
Embodiment 4
The distribution expression pattern of people hLDP gene
Electronics Northern express spectra.Press people's such as Ton C. method (Ton C et al., Biochem BiophysRes Commun 1997 Dec 18; 241 (2): 589-594; Hwang DM, et al., Circulation1997 Dec 16; 96 (12): 4146-4203), the BLAST retrieval will be done in the humanEST database of people hLDP cDNA sequence in the GCG software package, in the human EST that obtains, the EST of probable value＜10e-10, homogeny＞95% has 19, can be considered the transcriptional expression of this gene in tissue originally, draw the tissue spectrum of expressing this gene thus, find that it has expression in fetus spleen, retina, parathyroidoma, fetus liver, tire brain, fetus cochlea or the like tissue, show that it is bringing into play important effect in these histoorgans of human body.
Embodiment 5
The preparation and the purification of people hLDP polypeptide
In this embodiment, the people hLDP encoding sequence of total length or fragment are built into commercial protein merge among the expression vector, to express and purification of recombinant proteins.
People hLDP polypeptide is carried out prokaryotic expression with the form of gst fusion protein in intestinal bacteria.
Construction of prokaryotic expression vector, and transformed into escherichia coli
Complete encoding sequence (SEQ ID NO.6) according to people hLDP, design amplifies complete coding and reads the primer of frame (corresponding respectively to about 20 above Nucleotide of encoding sequence 5 ' and 3 ' end), and on positive anti-primer, introduce restriction endonuclease sites (this decides according to the pGEX-2T carrier of selecting for use) respectively, so that construction of expression vector.With the amplified production that obtains among the embodiment 1 is template, behind pcr amplification, with people hLDP gene guarantee to read be cloned under the correct prerequisite of frame the pGEX-2T carrier (Pharmacia, Piscataway, NJ).Identify that good expression vector utilizes CaCl
2Method changes bacillus coli DH 5 alpha over to, and Screening and Identification obtains containing the engineering bacteria DH5 α-pGEX-2T-hLDP of pGEX-2T-hLDP expression vector.
Express the isolation identification of the engineering bacteria of GST-hLDP recombinant protein
DH5 α-pGEX-2T-hLDP the engineering bacteria of picking list bacterium colony contains jolting overnight incubation in the LB substratum of 100 μ g/ml penbritins in 3ml, draw nutrient solution by 1: 100 concentration and in new LB substratum (containing 100 μ g/ml penbritins), cultivated about 3 hours, to OD
600After reaching 0.5, adding IPTG continues at 37 ℃ to final concentration 1mmol/L and cultivated respectively 0,1,2,3 hours.It is centrifugal to get the different 1ml bacterium liquid of incubation time, in the bacterial precipitation thing, add lysate (2 * SDS sample-loading buffer, 50 μ l, distilled water 45 μ l, 3-mercaptoethanol 5 μ l), the suspendible bacterial precipitation, boiled in the boiling water bath 5 minutes, centrifugal 1 minute of 10000rpm, supernatant adds electrophoresis in the 12%SDS-PAGE glue.The bacterial strain that the protein content of dyeing back observation expection molecular weight size increases with the IPTG induction time is the engineering bacteria of expressing the GST-hLDP fusion rotein.
The extraction purifying of GST-hLDP fusion rotein
The proteic engineering bacteria DH5 of abduction delivering GST-hLDP amalgamation and expression α-pGEX-2T-hLDP as stated above.Bacterium centrifugation after inducing adds the resuspended bacterium of 20ml PBS, ultrasonication bacterium by every 400ml bacterium.The ultrasonic completely liquid of broken bacterium adds 50% saturated Triptide Sepharose 4B of PBS by every milliliter of amount that adds 20 microlitres, 37 ℃ of joltings were in conjunction with 30 minutes, 10000rpm precipitated the Triptide Sepharose 4B that combines GST-hLDP in centrifugal 10 minutes, abandoned supernatant.Clean twice by the amount that every milliliter of ultrasonic liquid gained precipitation adds 100 μ l PBS, then add 10 μ l reduced glutathione elutriants by every milliliter of ultrasonic liquid gained precipitation, room temperature was put 10 minutes, centrifugal 10 minutes of 10000rpm, and supernatant is the fusion rotein of wash-out.Repeat twice of wash-out.The supernatant of wash-out is stored in-80 ℃, and carries out the SDS-PAGE electrophoresis, detects purification effect.Protein band at the 24kDa place promptly is a people hLDP albumen.
Embodiment 6
People hLDP albumen or polypeptide carry out eukaryotic cell expression in insect cell
1. the structure of people hLDP rhabdovirus expression vector and transfection Sf 9 insect cell strain
According to the complete encoding sequence (SEQ ID NO.6) of people hLDP, design amplifies the primer that complete coding is read frame, and introduces restriction endonuclease sites (this is decided by the carrier of selecting for use) respectively on positive anti-primer, so that construction of expression vector.With the amplified production that obtains among the embodiment 1 is template, behind pcr amplification, with people hLDP cDNA under the prerequisite that guarantees reading frame, be cloned into the pVL1392 carrier (InVitrogen, Carlsbad, CA).Identify good expression vector 3 μ g, wild-type linearized baculovirus dna (BaculoGold
TMACMNPV DNA, Pharmingen, San Diego, CA) 1 μ g and Lipofection (Gibco-BRL, NY) 25 μ L add in the insect substratum of 1ml serum-free, the 15 seconds mixings that vibrate, incubated at room 15 minutes is standby.Get 1ml (2 * 10
6) Sf9 insect cell suspension is in 60mm tissue culturing plate, change transfection media after adherent 1 hour, incubated at room was abandoned substratum after 15 minutes, add the dna vector transfection mixture for preparing previously, Parafilm seals culture plate, cultivated 4 hours in 27 ℃ of joltings of room temperature, then change perfect medium and cultivated 3 days, it is standby to collect supernatant.
2. change the Screening and Identification of the insect cell line of recombinant expression vector over to
The insect cell of transfection after 3 days made cell suspension (2 * 10 with fresh culture
6/ 1ml), get the 1ml cell suspension and place 60mm tissue culture ware, add the 3ml substratum, the culture supernatant that 100 μ l collect, adherent 1 hour, abandon the 2ml substratum, continue incubated at room temperature 1 hour, and discarded all substratum, add the 3ml semisolid medium that contains 20 μ l 4%X-gal of preheating, cultivate after 5-7 days picking white cell clone and in 96 well culture plates, cultivated 3-5 days, then draw supernatant infection Sf9 insect cell.
Collect the cell that infects and carry out the Western evaluation.The SDS-PAGE electrophoresis will be carried out after the lysis, glue behind the electrophoresis prints to protein transduction on the nitrocellulose membrane in the half-dried electrotransfer instrument of the Multiphor of Pharmacia II, nitrocellulose membrane is placed confining liquid sealing 1 hour, then in the antibody-solutions of anti-people hLDP, sealed 1 hour, the jolting of TBS liquid is cleaned 5 minutes 2 times totally, then film is placed the anti-second antibody solution jolting of biotin labeled anti-people hLDP one 1 hour, TBS cleans, adding avidin-alkaline phosphatase enzyme complex reacted 30 minutes, TBS cleans 2 times, adds freshly prepared colour developing liquid colour developing and observes protein band.
The Sf9 cell clone of picking high expression level people hLDP.
3. the proteic extraction purifying of people hLDP
Supernatant with the Sf9 cell clone of high expression level people hLDP infects the Sf9 cell in a large number, infects collecting cell after 48 hours, the PBS washing.Per 2 * 10
8Cell adds 20ml cell pyrolysis liquid (0.5%Triton X-100,20mM Na
3PO
4(sodium phosphate, pH7.8), 500mM NaCl, 1mM Na
3VO
4(vanadic acid sodium), 1mM Pefabloc, 1 μ g/ml pepstatin, leupeptin and aprotinin) broken cell, the centrifugal 20min of 12000 * g removes cell debris, and supernatant is by per 2 * 10
8Cell add 2ml NTA-agarose (Qiagen, Germany), 4 ℃ of absorption 1 hour.Then with containing the His damping fluid washed twice of 100nM imidazoles, with containing 20mM N, N '-two piperazine, 500mM NaCl, the buffer solution elution of 300mM imidazoles is to obtain the albumen of purifying.Elutriant is stored in 4 ℃, and carries out the proteic purity of people hLDP that the SDS-PAGE electrophoresis detection is extracted.Protein band at the 24kDa place promptly is a people hLDP albumen.
Embodiment 7
The preparation of anti-people hLDP antibody
1. the preparation of immune mouse and splenocyte: it is standby that the people hLDP albumen that obtains among embodiment 5 and the embodiment 6 is separated the back with chromatography, also can separate with the SDS-PAGE gel electrophoresis, electrophoretic band is cut off from gel, and with isopyknic complete Freund ' s adjuvant emulsion.Get the female mouse of 6-8 week Balb/C in age, the albumen with 50-100 μ g/0.2ml emulsification carries out peritoneal injection to mouse.After 14 days, with the same antigen of non-complete Freund ' s adjuvant emulsion to mouse with the dosage of 50-100 μ g/0.2ml again booster immunization once be used for after 3-5 days merging.Wherein, E Zheng chief editor, " tissue culture and molecular cell learn a skill ", Beijing Publishing House, the 210th page are seen in the splenocyte preparation.
2. by " tissue culture and molecular cell learn a skill " (the same), the method in the 371st page, preparation feeder cell.
3. by " tissue culture and molecular cell learn a skill " (the same), the method in the 213rd page is carried out cytogamy.
4. detection of antibodies: after cytogamy 10-15 days, need to check by the hole, in case find vigorous hybrid cell colony growth, the hLDP albumen of just should choosing is done the preliminary screening of antibody activity, and method commonly used has: immunofluorescent test, emission immunity test (RIA), enzyme linked immunosorbent assay (ELISA).After checking out the hole of antibody activity, clone cultivation at once, and isolate antibody.
Sequence table
＜110〉Research Center of Shanghai Human Genome
＜120〉human hLDP gene sequence, its proteins encoded and preparation method
<130>NP-10247
<160>7
<170>PatentIn version 3.2
<210>1
<211>50bp
<212>DNA
<213>Homo sapiens
1 GAGAGAGAGA GAGAGAGAGA ACTAGTCTCG AGTTTTTTTT TTTTTTTTTT
<210>2
<211>13bp
<212>DNA
<213>Homo sapiens
1 AATTCGGCAC GAG
<210>3
<211>9bp
<212>DNA
<213>Homo sapiens
1 GCCGTGCTC
<210>4
<211>20bp
<212>DNA
<213>Homo sapiens
1 GAGCGAGTCT TTTGCATCCT
<210>5
<211>20bp
<212>DNA
<213>Homo sapiens
1 GACTGAAGGG GACAGGAAGA
<210>6
<211>1701bp
<212>DNA
<213>Homo sapiens
<221>CDS
<222>(228)..(827)
<400>6
1 GAGCGAGTCT TTTGCATCCT GTTCCAGTCC ACATTTTCAG AAAGCATTTG
51 CTCAATTCGT CGCAAACTGG AATTACTACA GAAATTGTGT GAGACATTAA
101 AAAATGGCCC AGGGGTTATG CAGGTTCTAG GTTTGGTTCT TGCCTTTGGA
151 ACCTAACATG AATGGAGGAA ATAAGACTCG AGGACAGGCA GATGGCTTTG
201 GATTAGACAT TCTTCCAAAA CTGAAAGATG TCAAGAGCAG TGACAATAGC
251 AGAAGCCTTT TGTCATATAT TGTTTCGTAT TATCTCCGAA ATTTTGATGA
301 GGATGCTGGG AAAAGAACAG TGCCTCTTTC CACTGCCAGA ACCCCGGGAC
351 CTTTTTCAGG CCTCACAGAT GAAGTTTGAA GTTTTTCAAA AAGATCTCAG
401 AAAACTGAGG AAAGACTTGA AAGCCTGTGA AGTTGAAGCA GGGAAAGTAT
451 ACCAGGTCTC CTCAAAAGAG CATATGCAGC CTTTCAAGGA AAACATGGAA
501 CAATTTATTA TTCAAGCCAA AATTGACCAA GAGGCAGAGG AAAATTCACT
551 GACAGAGACT CATAAATGCT TTTTGGAGAC CACGGCATAT TTCTTCATGA
601 AACCAAAACT TGGAGAGAAG GAGGTGTCCC CAAATGCTTT CTTCAGTATC
651 TGGCATGAAT TCAGCTCTGA CTTTAAAGAC TTCTGGAAGA AAGAGAACAA
701 ACTTCTTCTA CAAGAGAGAG TAAAAGAAGC CGAAGAGGTG TGTAGACAGA
751 AGAAAGGAAA ATCACTTTAT AAAATAAAAC CAAGACATGA CTCTGGAATT
801 AAAGCAAAGA TAAGCATGAA AACTTGAACA TTGAAAAGCA GAATGAAAAT
851 GAGTCATTGC CACGACTTTC ACAAATTTCA GCTGACCTGA GAGTGGGAGG
901 GAAACTACCG TCATTCTGCT CATGTTTCTT CTTGACCTCT TGCATAATCT
951 TTTTGTTTTC TAGACAGTTC ACTAATTGTT GAATTTTACT GTATATTCAT
1001 ATAAAAATGC AAACGTACTA GACCAGTGGA GAATTTGACA CCTTTTCTTT
1051 TTGTAAAAGT TTATGGTATT ATACCGATAG ACCAAAACAG CATGTGTAAG
1101 AGGCAGTATC TGCACTAATT CTCAACATGC TAAACATTAA CTACAATTCA
1151 CTGTTGTGAG AATATTCCTC GTCACAGCAA AAACACTTTC CTTTCTACTG
1201 ACAACCAGTC CTCCACATCA CAGCATTTAG ACATATGGGT AAAATGTTAT
1251 TTCTAGTGAA TTGTTTGTAT CAGTTTCATG TCTAAGTATA AATTTTCTAT
1301 TTTAAAATTT AAGAACCGTT TATAATCAGT GCTTTCCCAA CTCTTGGGTT
1351 GCTCTCCATA ACTATGTATT TGTGAAAGAA AATGGTCATT TTTTTTTACT
1401 GAAGTCATAT AATGACTTGG GTCAGCTCGT AATGCATTGT GATGGTTTTG
1451 TATGAGCTGG GTGTTTTTTT CCATTACTTT TAATGATCTT CGTTGCAAGT
1501 TATAGTTGTG GATAAAGGGG AGAATTTATT GCTCTTGCAA ACCAATTATG
1551 GAAAGCAACT TAAGAAAACC AATGTTCTAA ATCATAATTG TTTGTATTTA
1601 TGTAAAGTAT GGTCTCTTAC TTTTTAGTTT GTAGTTTAAG TGCAAAGAAA
1651 CAGTAGTGGT TTTTTTTCTA TTGTTTTGTA GTCTTCCTGT CCCCTTCAGT
1701 C
<210>7
<211>199bp
<212>PRT
<213>Homo sapiens
1 MSRAVTIAEA FCHILFRIIS EILMRMLGKE QCLFPLPEPR DLFQASQMKF
51 EVFQKDLRKL RKDLKACEVE AGKVYQVSSK EHMQPFKENM EQFIIQAKID
101 QEAEENSLTE THKCFLETTA YFFMKPKLGE KEVSPNAFFS IWHEFSSDFK
151 DFWKKENKLL LQERVKEAEE VCRQKKGKSL YKIKPRHDSG IKAKISMKT
Claims (11)
1. isolated dna molecular, it is characterized in that, it comprises: coding has the nucleotide sequence of the polypeptide of people hLDP protein active, and shows at least 70% homology from the nucleotides sequence of Nucleotide 228-827 position among described nucleotide sequence and the SEQ ID NO.6; Perhaps described nucleotide sequence can be under the moderate stringent condition with SEQ ID NO.6 in from the nucleotide sequence hybridization of Nucleotide 228-827 position.
2. dna molecular as claimed in claim 1 is characterized in that described sequence encoding has the polypeptide of the aminoacid sequence shown in the SEQ IDNO.7.
3. dna molecular as claimed in claim 1 is characterized in that, this sequence has among the SEQ ID NO.6 nucleotide sequence from Nucleotide 228-827 position.
4. isolated people hLDP protein polypeptide is characterized in that it comprises: have polypeptide or its conservative property variation polypeptide or its active fragments of SEQID NO.7 aminoacid sequence, or its reactive derivative.
5. polypeptide as claimed in claim 4 is characterized in that, this polypeptide is to have SEQ ID NO.7 polypeptide of sequence.
6. a carrier is characterized in that, it comprises the described DNA of claim 1.
7. one kind with the described carrier transformed host cells of claim 6, it is characterized in that it comprises prokaryotic cell prokaryocyte and eukaryotic cell.
8. a generation has the method for the polypeptide of people hLDP protein active, is characterised in that its step is as follows:
(1) nucleotide sequence that coding is had a polypeptide of people hLDP protein-active operationally is connected in expression regulation sequence, form people hLDP protein expression vector, show at least 70% homology from the nucleotides sequence of Nucleotide 228-827 position among described nucleotide sequence and the SEQ ID NO.6;
(2) change the expression vector in the step (1) over to host cell, form the proteic reconstitution cell of people hLDP;
(3) under the condition that is fit to expressing human hLDP protein polypeptide, the reconstitution cell in the culturing step (2);
(4) isolate polypeptide with people hLDP protein-active.
9. energy and the described people hLDP of claim 7 protein polypeptide specificity bonded antibody is characterized in that it comprises polyclonal antibody and monoclonal antibody.
10. a nucleic acid molecule is characterized in that, it comprises 8-100 continuous nucleotide in the described dna molecular of claim 1.
11. one kind is used for the method whether test sample exists people hLDP nucleotide sequence, it is characterized in that it comprises with described probe of claim 10 and sample hybridizes, whether detection probes combination has taken place then, this sample is the product behind the pcr amplification, wherein the pcr amplification primer is corresponding to people hLDP nucleotide coding sequence, and can be positioned at the both sides or the centre of this encoding sequence, primer length is 15～50 Nucleotide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510111047 CN1978642A (en) | 2005-12-01 | 2005-12-01 | Human hLDP gene sequence, and its coded protein and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510111047 CN1978642A (en) | 2005-12-01 | 2005-12-01 | Human hLDP gene sequence, and its coded protein and preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1978642A true CN1978642A (en) | 2007-06-13 |
Family
ID=38129949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510111047 Pending CN1978642A (en) | 2005-12-01 | 2005-12-01 | Human hLDP gene sequence, and its coded protein and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1978642A (en) |
-
2005
- 2005-12-01 CN CN 200510111047 patent/CN1978642A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU711113B2 (en) | Novel serpin derived from human hypothalamus | |
| CN1978642A (en) | Human hLDP gene sequence, and its coded protein and preparing method | |
| CN1978653A (en) | Human hlipase gene sequence, and its coded protein and preparing method | |
| WO1997006262A1 (en) | Non-receptor type human protein tyrosine phosphatase | |
| CN1978456A (en) | Human hNit3-ase gene sequence, and its coded protein and preparing method | |
| CN1978646A (en) | Human hNmrr gene sequence, and its coded protein and preparing method | |
| CN1978647A (en) | Human hN027 gene sequence, and its coded protein and preparing method | |
| CN1978648A (en) | Human hNRBF2 gene sequence, and its coded protein and preparing method | |
| CN1277998A (en) | Human nitrile hydrolytic enzyme protein and coding series thereof | |
| CN1978643A (en) | Human hMSC gene sequence, and its coded protein and preparing method | |
| CN1978455A (en) | Human hNDS4-iso gene sequence, and its coded protein and preparation method | |
| CN1289848A (en) | Human interleukin enhancer binding factor protein isomer and its coding sequency | |
| CN1289849A (en) | Human protein isomer induced by tumor nectosis factor and its coding sequence | |
| CN1270221A (en) | Human adenosine triphosphatase subunit protein and its coding sequence | |
| CN1281895A (en) | Human mitochondrial solute carrier protein isomer and its code sequence | |
| CN1978645A (en) | Human hNIF3 s gene sequence, and its coded protein and preparing method | |
| CN1978644A (en) | Human hNGT gene sequence, and its coded protein and preparing method | |
| CN1289853A (en) | Human micronuclear ribonucleoprotein isomer and its coding sequence | |
| CN1270222A (en) | Human coenzyme I subunit isomer protein and its coding sequence | |
| CN1281896A (en) | Human nuclear receptor factor protein an its code sequence | |
| CN1281045A (en) | Human fibrous surface structure subunit protein and its coding sequence | |
| CN1271009A (en) | New human diacyl glyceropyrophosphate phosphatase protein and its code sequence | |
| CN1269409A (en) | New human mitochondrion solute carrier protein and its code sequence | |
| CN1283692A (en) | A new human nerve cell olfactory-related protein and its coding sequence | |
| CN1281043A (en) | Human early endosome antigen protein isomer and its coding sequence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |